| |
| |
|
| Insider
Information: |
Bolzon Bradley J Phd |
| Relationship: |
Director, 10% Owner |
| City: |
Menlo Park |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
21,851 |
|
|
Indirect Shares
|
13,354,534 |
|
|
| Direct
Value |
$104,448 |
|
|
|
Indirect Value
|
$82,868,260 |
|
|
| Total
Shares |
13,376,385 |
|
|
| Total
Value |
$82,972,707 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
-1.0
|
| Percentage
Gain/Loss : |
 -15.0%
|
-33.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Paratek Pharmaceuticals Inc |
PRTK |
10% Owner |
2006-05-15 |
0 |
2006-05-15 |
13,713 |
Premium* |
|
|
Flexion Therapeutics Inc |
FLXN |
Director, 10% Owner |
|
0 |
2014-02-18 |
3,206,807 |
Premium* |
|
|
Phaserx, Inc. |
PZRX |
10% Owner |
|
0 |
2016-05-23 |
1,931,094 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
Director |
2021-06-29 |
0 |
2021-07-19 |
498,558 |
Premium* |
|
|
Black Diamond Therapeutics, Inc. |
BDTX |
Director, 10% Owner |
2020-12-14 |
21,851 |
2020-12-14 |
5,606,424 |
Premium* |
|
|
Monte Rosa Therapeutics, Inc. |
GLUE |
Director, 10% Owner |
2021-06-28 |
0 |
2021-06-28 |
2,097,938 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
134 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2019-10-30 |
4 |
AS |
$51.89 |
$1,089,675 |
D/D |
(21,000) |
13,745 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
9,658,157 |
2,130,579 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • – |
2020-02-03 |
4 |
B |
$19.00 |
$16,999,984 |
I/I |
894,736 |
1,206,603 |
2.1 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-06-22 |
4 |
AS |
$72.51 |
$725,069 |
I/I |
(10,000) |
584,190 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-06-23 |
4 |
AS |
$75.35 |
$753,453 |
I/I |
(10,000) |
574,190 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-07-06 |
4 |
AS |
$82.16 |
$1,647,730 |
I/I |
(20,000) |
554,190 |
0 |
% |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-07-27 |
4 |
A |
$0.00 |
$0 |
I/I |
6,495 |
1,177 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,491 |
1,491 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-07-27 |
4 |
AS |
$0.00 |
$0 |
I/I |
(335,712) |
0 |
0 |
% |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-10 |
4 |
AS |
$33.04 |
$205,398 |
I/I |
(6,217) |
6,803,922 |
0 |
% |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-11 |
4 |
AS |
$33.08 |
$250,591 |
I/I |
(7,575) |
6,797,230 |
0 |
% |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-12 |
4 |
A |
$0.00 |
$0 |
I/I |
11,176 |
5,176 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-12 |
4 |
AS |
$0.00 |
$0 |
D/D |
(300,000) |
6,497,230 |
0 |
% |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-12 |
4 |
AS |
$0.00 |
$0 |
I/I |
(11,176) |
0 |
0 |
% |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,718 |
3,209 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-18 |
4 |
A |
$0.00 |
$0 |
I/I |
11,176 |
5,176 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,718 |
4,927 |
0 |
- |
|
| BDTX |
Black Diamond Therapeutic... |
Director |
– • • |
2020-08-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(311,176) |
0 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-09-01 |
4 |
S |
$91.27 |
$5,550,644 |
I/I |
(60,000) |
0 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-09-01 |
4 |
OE |
$13.62 |
$1,513,950 |
I/I |
60,000 |
60,000 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-09-09 |
4 |
AS |
$0.00 |
$0 |
I/I |
(207,408) |
0 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-09-09 |
4 |
A |
$0.00 |
$0 |
I/I |
42,272 |
42,272 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
7,391 |
7,391 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-09-10 |
4 |
AS |
$85.03 |
$1,949,996 |
I/I |
(22,845) |
531,345 |
0 |
% |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2020-09-14 |
4 |
AS |
$84.89 |
$98,045 |
I/I |
(1,155) |
530,190 |
0 |
% |
|
134 Records found
|
|
Page 2 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
